Dideoxycytidine for AIDS
Executive Summary
HHS is seeking an industry sponsor to collaborate in the preclinical and clinical development of the antiviral for treatment of AIDS. In the Oct. 14 Federal Register, HHS reported that National Cancer Institute scientists have shown dideoxycytidine "is effective in inhibiting in vitro growth of HTLV-III, the etiologic agent of AIDS." The agency said the industry sponsor will be granted an exclusive royalty-bearing license, while the U.S. government will receive "reasonable royalties".
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.